CYTOSORBENTS CORP's ticker is CTSO and the CUSIP is 23283X206. A total of 95 filers reported holding CYTOSORBENTS CORP in Q4 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $224 | -47.5% | 119,100 | +0.2% | 0.00% | -100.0% |
| Q2 2023 | $427 | +6.8% | 118,900 | +0.3% | 0.00% | 0.0% |
| Q1 2023 | $400 | +117.4% | 118,600 | +0.2% | 0.00% | – |
| Q4 2022 | $184 | -99.9% | 118,400 | -40.1% | 0.00% | – |
| Q3 2022 | $269,000 | -12.4% | 197,796 | +41.2% | 0.00% | – |
| Q2 2022 | $307,000 | +13.3% | 140,120 | +65.0% | 0.00% | – |
| Q1 2022 | $271,000 | -74.4% | 84,900 | -39.4% | 0.00% | -100.0% |
| Q2 2021 | $1,058,000 | -32.3% | 140,100 | -22.2% | 0.00% | -50.0% |
| Q1 2021 | $1,562,000 | +167.9% | 180,000 | +146.2% | 0.00% | +100.0% |
| Q4 2020 | $583,000 | -23.9% | 73,100 | -23.9% | 0.00% | 0.0% |
| Q3 2020 | $766,000 | +160.5% | 96,000 | +147.4% | 0.00% | – |
| Q1 2019 | $294,000 | -70.1% | 38,800 | -68.1% | 0.00% | -100.0% |
| Q4 2018 | $983,000 | -62.6% | 121,700 | -47.2% | 0.00% | 0.0% |
| Q2 2018 | $2,625,000 | – | 230,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CM Management, LLC | 450,000 | $846,000 | 0.90% |
| Skylands Capital, LLC | 2,944,670 | $5,535,980 | 0.84% |
| Sargent Investment Group, LLC | 1,257,048 | $2,363,250 | 0.57% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 197,940 | $372,127 | 0.52% |
| Avenir Corp | 2,717,397 | $5,108,706 | 0.48% |
| Granahan Investment Management | 1,552,393 | $2,918,499 | 0.10% |
| Seelaus Asset Management LLC | 20,450 | $38,446 | 0.04% |
| HighMark Wealth Management LLC | 10,000 | $18,800 | 0.02% |
| Key Client Fiduciary Advisors, LLC | 13,000 | $24,440 | 0.02% |
| Eudaimonia Partners, LLC | 23,500 | $44,180 | 0.01% |